# Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort

> **NCT07268664** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Beijing Chest Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Rifampicin Resistant Tuberculosis
- Pulmonary Tuberculosis
- Tuberculosis
- Drug-resistant Tuberculosis

## Interventions

- **DRUG:** BLMZ

## Key facts

- **NCT ID:** NCT07268664
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07268664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07268664, "Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07268664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*